Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave's Q4 Revenues Rise 17-Percent; 85 Percent of '07 Receipts to Come From Dxs

NEW YORK (GenomeWeb News) — Third Wave Technologies today said fourth-quarter revenues increased 17 percent as R&D spending nearly doubled and net loss narrowed 8 percent.  
Total receipts for the three months ended Dec. 31, 2006, increased to $6.8 million from $5.8 million year over year.
Revenue from molecular diagnostics rose to $5.8 million from $4.3 million, but receipts from research products declined to $954,000 from $2.4 million.
R&D expenses doubled to $3.6 million compared with $1.8 million the previous year.
CEO Kevin Conroy said the company “met or exceeded” its 2006 objectives and said it met its product-development goals for the year, including starting clinical trials for HPV products and submitting a cystic fibrosis diagnostic test for FDA approval.
Net loss for the periods declined to $4.6 million from $5 million year over year.
Third Wave had around $44.2 million in cash, cash equivalents, and short-term investments as of Dec. 31.
The company said it expects 2007 revenue to be between $31 million and $33 million, or an improvement of between 10.7 percent and 17.8 percent year over year. Third Wave said that between $26 million and $28 million of this year’s revenue will come from molecular diagnostics.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.